Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. DDW provides an update.
GenScript Biotech Corporation: GenTitan Gene Fragments Synthesis service
Powered by GenScript’s miniature semiconductor chip (MSC) technology, GenTitan gives scientists access to high-throughput, synthetic DNA, to accelerate progress in the fields of synthetic biology, protein and antibody engineering, metabolism studies, genomic research, virology, and immunology.
DNA Script: SYNTAX DNA printing platform
Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.
Broughton: new inhalation testing service
The service is designed to help pharmaceutical companies bring orally inhaled and nasal drug products (OINDPs) to market efficiently. It will focus on formulation and device testing for dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs), soft mist inhalers (SMIs), nasal sprays, breath-actuated devices, and novel inhaled devices.
Torx Software: spring software release
The spring release is designed to further enhance CRO management capabilities. The modular, cloud native Torx platform enables chemistry teams to collaborate and share molecules, both internally and with contract research organisations (CROs) around the world.
Astera Software: Astera API Management
The new product is a no-code, automated, unified platform for complete API lifecycle management and integrations. It is accessible, boosts developer productivity and aims to save up to 80% of the time and cost associated with traditional API management strategies.
Gyros Protein Technologies: Gyrolab Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents
The kit reagents are for the detection of circulating immune complexes of human IgG with cyno anti-human IgG. They are designed to streamline pre-clinical development of antibody-based therapeutics, enabling immunogenicity screening of drug candidates without the need for drug-specific ADA assay development.
Cytiva: X-platform bioreactors
X-platform bioreactors, initially available in 50 and 200 L sizes are provided with Figurate automation solution software and can increase process efficiency through ergonomic improvements, production capability and simplified supply chain operations. The bioreactors also work with the Cytiva Bioreactor Scaler.
